Molecular characteristics of incidental lower-grade glioma for treatment decision-making

Author:

Park Jeongman1,Sim Jeongmin1,Ahn Juwon1,Kim Yu Jin1,Hwang Sojung2,Cho Kyunggi1,Chang Da-Young3,Jung Jin-Hwa3,Moon Ju Hyung4,Sung KyoungSu5,Lim Jaejoon1

Affiliation:

1. Department of Neurosurgery, Bundang CHA Medical Center, CHA University, Seongnam;

2. Global Research Supporting Center, Bundang CHA Medical Center, CHA University, Seongnam;

3. Research Center, CelleBrain Ltd., Jeonju;

4. Department of Neurosurgery, Brain Tumor Center, Severance Hospital, Yonsei University College of Medicine, Seoul; and

5. Department of Neurosurgery, Dong-A University Hospital, Dong-A University College of Medicine, Busan, Korea

Abstract

OBJECTIVE Several limitations are associated with the early diagnosis and treatment of incidental lower-grade glioma (iLGG), and due to its unknown molecular features, its management is categorized as either the “wait-and-see” strategy or immediate treatment. Therefore, in this study the authors explored iLGG’s clinical and molecular landscape to improve its management. METHODS The authors retrospectively assessed the differences between the molecular and clinical characteristics of iLGG and symptomatic lower-grade glioma (sLGG) samples filtered based on symptom data corresponding to The Cancer Genome Atlas cohort with mutations. Thereafter, genomic and transcriptomic analysis was performed. RESULTS There was no significant difference between iLGG and sLGG with respect to mutation status; however, there was an increase in the interaction between major mutations in sLGG, depending on the histological subtype and the IDH1 mutation status. Furthermore, the IDH1 mutation characteristics corresponding to wild-type glioma were much more obvious in sLGG than in iLGG. Additionally, in sLGG, genes associated with malignancy, including cell proliferation–related, cell migration–related, epithelial-to-mesenchymal transition–related, and negative regulation of cell death–related genes, were significantly upregulated, and groups showing higher expression levels of these genes were associated with worse prognosis. Also, 8 of the 75 identified upregulated genes showed positive correlation with resistance to the drugs that are normally used for glioma treatment, including procarbazine, carmustine, vincristine, and temozolomide. CONCLUSIONS The new insights regarding the different molecular features of iLGG and sLGG indicated that the immediate management of iLGG could result in better prognosis than the wait-and-see strategy.

Publisher

Journal of Neurosurgery Publishing Group (JNSPG)

Subject

Genetics,Animal Science and Zoology

Reference40 articles.

1. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018;Ostrom QT,2021

2. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013;Ostrom QT,2016

3. Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline;Mohile NA,2022

4. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood;Weller M,2021

5. Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas;Jo J,2022

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3